Recent Studies Validate High performance and Accurate Results for UltraMAB®OTI1A4 as an Effective Screening Tool for ALK Translocation in Non-Small Cell Lung Cancer patients.

Rockville, MD – April 14, 2016. A pair of recently published studies shed light on the highly interesting area on detection of ALK expression among NSCLC patients by IHC. One study was conducted by NordiQC (Aalborg, Denmark), the other by a group of Germany scientists and was published in the Journal of Thoracic Oncology. Both studies compared the performance of OTI1A4 antibody from OriGene (Rockville, MD) and the D5F3 antibody from Ventana (Tucson, AZ) in a large set of lung cancer specimens with known ALK status identified by FISH assay.

Read More
Posted in Antibody News By Acris Antibodies

  is now part of  

We have combined our strengths to support the research community even better and to help you make the most out of your research budget: Get high quality antibodies from OriGene´s throughly validated antibody lines, TrueMAB™ and UltraMAB™ AND now even save 40 % of the regular price*!

Read More
Posted in Promotions By Acris Antibodies

Acris Antibodies is now offering OriGene antibodies!

OriGene applies advanced technologies to generate better antigens, aiming to provide better antibodies for successful assays. A corresponding positive control for WB is available if applicable.

Here we introduce to you OriGene's highly validated antibody lines, TrueMAB™ and UltraMAB™!

Read More
Posted in Antibody News By Acris Antibodies
  • LinkedIn